On April 30, the Ministry of Food and Drug Safety announced that it has approved the imported orphan drug “Tepezza (teprotumumab)” for the treatment of adult patients (aged 18 and over) with moderate to severe thyroid eye disease.


Food and Drug Safety Administration building. Photo by Yonhap News

Food and Drug Safety Administration building. Photo by Yonhap News

View original image

Thyroid eye disease is an autoimmune disorder in which autoantibodies attack the muscles and fat tissues around the eyes, causing abnormal reactions.


Tepezza is an orphan drug that specifically blocks the insulin-like growth factor-1 receptor (IGF-1R) signaling pathway, thereby controlling the inflammation and autoimmune pathophysiology in patients with thyroid eye disease. By inhibiting the underlying immune mechanism, it can prevent orbital inflammation and excessive synthesis of extracellular matrix and tissue proliferation, which lead to exophthalmos and diplopia—symptoms characteristic of thyroid eye disease.


This is the first approval in Korea for a thyroid eye disease treatment. As the first IGF-1R inhibitory therapy for this condition, it is expected to give patients a non-surgical treatment option.


The Ministry designated this drug as the 42nd product under the Global Innovative Product Fast-Track (GIFT) review system, and conducted an expedited review. GIFT is a program that supports the rapid commercialization of global innovative medical products from the early stages of clinical development.


The Ministry stated, “We will continue to do our best, based on regulatory science expertise, to ensure that new therapies with proven safety and efficacy are promptly supplied to patients with rare diseases.”





This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing